CVS HEALTH Corp (CVS) stock

CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 19/3029% below fair value

$89.79+0.27 (+0.30%)

Close on Nov 12, 2026Market cap $114.84BP/E 10.5Yield 2.96%

Cvs Health r&d expenses

Research and development expenses are spending on new products and technology.

Cvs Health has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CVS.

Revenue growth6.7% · median 6.8%

Gross margin44.2% · median 20.7%

Operating margin3.6% · median 2.7%

Net margin2.6% · median 2.1%

Advertisement
300 × 250

See a number that looks wrong?